tldrdailynews.com logo

"Wegovy: FDA Approval for Heart Health Benefits Signals Potential Insurance Coverage Expansion"

1 min read
Source: CNBC
"Wegovy: FDA Approval for Heart Health Benefits Signals Potential Insurance Coverage Expansion"
Photo: CNBC
TL;DR

The FDA has approved Novo Nordisk's weight loss drug Wegovy for reducing the risk of serious cardiovascular complications in adults with obesity and heart disease, marking the first time a weight loss medication has gained expanded use for preventing life-threatening cardiovascular events. The approval could expand insurance coverage for the costly drug and similar treatments for obesity. Wegovy, which mimics a gut hormone to suppress appetite, showed a 20% reduction in the overall risk of heart attack, stroke, and death from cardiovascular causes in a landmark phase three trial. This move could also help Novo Nordisk maintain its lead over competitors in the weight-loss drug market.

Topics:businesshealth-pharmaceuticals#cardiovascular-disease#fda-approval#health-pharmaceuticals#novo-nordisk#obesity#wegovy
Share this article
  1. Novo Nordisk's Wegovy wins FDA approval for heart health benefits, in move that could expand insurance coverage  CNBC
  2. Obesity drug Wegovy is approved to cut heart attack and stroke risk in overweight patients  Yahoo Finance
  3. Novo Nordisk Stock Slumps Despite Winning Approval For Weight-Loss Drug For Heart Benefit  Investor's Business Daily
  4. FDA approves weight-loss drug Wegovy to reduce heart-disease risks  The Washington Post
  5. Weight loss drug Wegovy approved for heart health  The Hill

Want the full story? Read the original reporting

Read on CNBC